Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Kymera Therapeutics
Biotech
Sanofi backs protein degrader after glimpse of clinical efficacy
In a small phase 1 trial, Kymera linked the IRAK4 candidate to improvements in symptoms, encouraging its partner Sanofi to take the program forward.
Nick Paul Taylor
Dec 14, 2022 7:00am
Earnings arrive after dreadful 6 months, but readouts offer hope
Jul 18, 2022 9:42am
Kymera’s protein degrader shows potential to boost I-O
Nov 24, 2021 9:00am
Don't blink: PAQ gobbles up $30M series A to ink autophagy era
Jul 15, 2021 6:00am
Kymera, fresh off a $2B Sanofi pact, guns for an IPO
Aug 2, 2020 5:32am
Sanofi pays $150M upfront, $2B in biobucks for Kymera I&I deal
Jul 9, 2020 7:00am